Search research articles
Contact Us
Filters
Showing results (301-310 of 359) with videos related to
Page
of 36
Sort By:
British Journal of Cancer
|
December 23, 1998
Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening
E Boven, H M Pinedo, A H van Hattum, et al.
The American Journal of Pathology
|
June 17, 1998
An antibody raised against a conserved sequence of the prion protein recognizes pathological isoforms in human and animal prion diseases, including Creutzfeldt-Jakob disease and bovine spongiform encephalopathy
P Piccardo, J P Langeveld, A F Hill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 4, 2003
Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923)
V C G Tjan-Heijnen, S Caleo, P E Postmus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2001
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients
H H Backus, D F Dukers, C J van Groeningen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 21, 2013
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
S Ramalingam, J Crawford, A Chang, et al.
Clinical Drug Investigation
|
March 29, 2008
Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens
V R Nannan Panday, L J van Warmerdam, M T Huizing, et al.
British Journal of Cancer
|
September 1, 1996
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group
J van Meerbeeck, C Debruyne, N van Zandwijk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2008
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
P A Zucali, M G Ruiz, E Giovannetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 14, 2006
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975
F Efficace, A Bottomley, E F Smit, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 21, 1998
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group
N van Zandwijk, H J Groen, P E Postmus, et al.
Page
of 36
Search research articles
Search
Showing results (301-310 of 359) with videos related to
Sort By:
Page
of 36
British Journal of Cancer
|
December 23, 1998
Characterization of human soft-tissue sarcoma xenografts for use in secondary drug screening
E Boven, H M Pinedo, A H van Hattum, et al.
The American Journal of Pathology
|
June 17, 1998
An antibody raised against a conserved sequence of the prion protein recognizes pathological isoforms in human and animal prion diseases, including Creutzfeldt-Jakob disease and bovine spongiform encephalopathy
P Piccardo, J P Langeveld, A F Hill, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 4, 2003
Economic evaluation of antibiotic prophylaxis in small-cell lung cancer patients receiving chemotherapy: an EORTC double-blind placebo-controlled phase III study (08923)
V C G Tjan-Heijnen, S Caleo, P E Postmus, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2001
5-Fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients
H H Backus, D F Dukers, C J van Groeningen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 21, 2013
Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial)
S Ramalingam, J Crawford, A Chang, et al.
Clinical Drug Investigation
|
March 29, 2008
Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens
V R Nannan Panday, L J van Warmerdam, M T Huizing, et al.
British Journal of Cancer
|
September 1, 1996
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group
J van Meerbeeck, C Debruyne, N van Zandwijk, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 10, 2008
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
P A Zucali, M G Ruiz, E Giovannetti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 14, 2006
Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975
F Efficace, A Bottomley, E F Smit, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 21, 1998
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group
N van Zandwijk, H J Groen, P E Postmus, et al.
Page
of 36